Carregant...
Biosimilar Insulin and Costs: What Can We Expect?
The costs for insulin treatment are high, and the steady increase in the number of patients with diabetes on insulin presents a true challenge to health care systems. Therefore, all measures to lower these costs are welcomed by patients, physicians, and health care providers. The market introduction...
Guardat en:
| Publicat a: | J Diabetes Sci Technol |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4773960/ https://ncbi.nlm.nih.gov/pubmed/26350722 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1932296815605337 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|